Roche Continues Support to Fight Global Mpox Outbreak
Roche Announces Continued Commitment
Roche (SIX: RHHBY) announced its ongoing support in addressing the global mpox emergency by partnering with healthcare providers.
The company is actively working with its partners to enhance diagnostic testing and provide necessary support to combat the mpox outbreak.
Roche's Diagnostic Tests
Developed for Monkeypox Virus
Roche has developed diagnostic tests specifically designed to detect the monkeypox virus.
These tests are essential for early detection and accurate diagnosis of mpox, enabling timely treatment and containment measures.
Roche's Commitment
Supporting International Response
Roche's support is part of the international response to the mpox outbreak declared a global health emergency by the World Health Organization (WHO).
The company is collaborating with healthcare authorities and organizations worldwide to ensure the availability of its diagnostic tests and expertise.
Mpox Outbreak
Ongoing Global Health Emergency
Mpox is a rare but potentially serious viral infection that can spread through close contact with an infected person or animal.
Symptoms can include fever, headache, muscle aches, swollen lymph nodes, and a characteristic rash.
Early Detection and Diagnosis
Crucial for Containment
Early detection and accurate diagnosis of mpox are crucial for effective containment measures.
Roche's diagnostic tests play a vital role in helping healthcare providers quickly identify and isolate infected individuals.
Accelerated Research and Development
Roche is also actively involved in research and development efforts to further improve mpox diagnostics and treatments.
The company is committed to advancing scientific knowledge and developing innovative solutions to address this global health challenge.
Additional Information
For more information on Roche's response to the mpox outbreak, please visit the company's website: https://www.roche.com/media/releases/med-cor-2022-08-20.htm
Comments